Skip to main content

Table 1 In vivo toxicity study of BU-32 compared with Bortezomib

From: BU-32: a novel proteasome inhibitor for breast cancer

 

Untreated control

BU-32

Bortezomib

  

0.1 mg/kg

0.25 mg/kg

0.1 mg/kg

0.25 mg/kg

Total number of mice/group

10

10

10

10

10

Week 1

10

10

10

10

9

Week 2

10

10

8

8

1

  1. Ten mice in each group were treated twice a week for 2 weeks with vehicle (control) or with 0.1 and 0.25 mg/kg BU-32 and Bortezomib. BU-32-treated mice showed more tolerance than Bortezomib at higher dose (0.25 mg/kg), and the lower dose of BU-32 (0.1 mg/kg) was completely safe to the animals after 2 weeks of treatment.